ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc (CDT)

0,1073
0,0021
(2,00%)
Geschlossen 07 November 10:00PM
0,1079
0,0006
(0,56%)
Nach Börsenschluss: 1:55AM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
0,1079
Gebot
0,1063
Fragen
0,108
Volumen
11.418.766
0,1053 Tagesbereich 0,118
0,0789 52-Wochen-Bereich 7,7509
Marktkapitalisierung
Handelsende
0,1052
Handelsbeginn
0,1071
Letzte Trade
3
@
0.108
Letzter Handelszeitpunkt
Finanzvolumen
US$ 1.246.524
VWAP
0,109165
Durchschnittliches Volumen (3 Mio.)
14.429.346
Ausgegebene Aktien
96.004.699
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-267,04
Gewinn pro Aktie (EPS)
-0,06
Erlöse
-
Nettogewinn
-6,06M

Über Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company¿s licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company¿s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto¿s Thyroiditis. The Company¿s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto¿s Thyroiditis (HT) and Graves¿ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto¿s Thyroiditis and Graves¿ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Conduit Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CDT. The last closing price for Conduit Pharmaceuticals was US$0,11. Over the last year, Conduit Pharmaceuticals shares have traded in a share price range of US$ 0,0789 to US$ 7,7509.

Conduit Pharmaceuticals currently has 96.004.699 shares in issue. The market capitalisation of Conduit Pharmaceuticals is US$10,10 million. Conduit Pharmaceuticals has a price to earnings ratio (PE ratio) of -267.04.

CDT Neueste Nachrichten

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor...

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a...

Conduit Pharmaceuticals to Join Russell 3000® Index

SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market...

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), an internally managed, diversified real estate investment...

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its...

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge...

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.00413.949903660890.10380.11310.078976388360.09774753CS
40.00292.76190476190.1050.15740.0789279278210.11575752CS
12-0.0823-43.27024185070.19020.2040.0789144293460.12117455CS
26-2.9121-96.42715231793.023.50.0789115372810.15547767CS
52-1.1521-91.43650793651.267.75090.078958829920.18843339CS
156-12.4921-99.143650793712.612.890.078953379150.21895079CS
260-12.4921-99.143650793712.612.890.078953379150.21895079CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CONLGraniteShares ETF Trust GraniteShares
US$ 43,12
(61,62%)
24,47M
ARBBARB IOT Group Ltd
US$ 0,802709
(42,20%)
224,6M
ELWSEarlyworks Co Ltd
US$ 6,00
(41,18%)
6,05M
CTKBCytek Biosciences Inc
US$ 7,40
(36,03%)
4,17M
TMCITreace Medical Concepts Inc
US$ 7,78
(35,07%)
3,13M
BNOXBionomics Ltd
US$ 0,2839
(-42,41%)
17,56M
VSTEVast Renewable Ltd
US$ 3,09
(-42,35%)
2,65M
ZCARZoomcar Holdings Inc
US$ 7,6899
(-41,74%)
1,33M
ZVSAZyVersa Therapeutics Inc
US$ 1,5242
(-39,99%)
2,07M
TNGXTango Therapeutics Inc
US$ 3,22
(-37,84%)
14,86M
ELABElevai Labs Inc
US$ 0,0173
(-19,16%)
306,06M
NVDANVIDIA Corporation
US$ 145,61
(4,07%)
235M
ARBBARB IOT Group Ltd
US$ 0,802709
(42,20%)
227,42M
SQQQProShares UltraPro Short QQQ
US$ 6,6503
(-8,02%)
217,37M
DJTTrump Media and Technology Group Corporation
US$ 35,955
(5,94%)
169,76M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock